Chronic Myeloid Leukemia (CML)
Chronic Myeloid Leukemia is a myeloproliferative neoplasm driven by the BCR-ABL1 fusion gene. Molecular monitoring is central to diagnosis and disease management.
Biomarkers used in this indication
Each approval combines this indication with specific biomarker criteria and a therapy. Select a therapy from the tables below to open its FDA-defined testing pathway.
Defined explicitly for Chronic Myeloid Leukemia (CML) in FDA labeling.
| Biomarker | Biomarker criteria | Therapies |
|---|---|---|
| t(9;21) Philadelphia chromosome |
|
Defined at the solid tumor level and applicable to Chronic Myeloid Leukemia (CML) and other solid tumor cancers.
No tumor-agnostic biomarker approvals are currently mapped for this indication.
Therapies with biomarker-defined approvals
Each therapy below has at least one FDA companion diagnostic approval tied to Chronic Myeloid Leukemia (CML). Select a therapy to view the specific approval and eligible tests.
t(9;21) Philadelphia chromosome (BCR-ABL fusion)